COMPANY

Pulmatrix

Keywords: respiratory migraine inhaled pulmonary disease allergic bronchopulmonary aspergillosis Chronic Obstructive Pulmonary Disease Asthma Postoperative Wound Infection-deep Post Operative Wound Infection Irritation/Irritant Cystic Fibrosis Lung Diseases Bronchial Diseases PUR118 PUR003 PUR0200 PUR3100 PUR1800 PUR1900 RUT058-60

Profile checked Oct 10, 2026

15Trials (company is sponsor)5NIH grants

Timeline

Feb 1, 2023 Trial start Phase 2: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA source ↗
Jun 9, 2022 Trial start Phase 1: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults source ↗
Jan 4, 2021 Trial start 1: A Phase 1b Study of PUR1800 in Patients With COPD source ↗
Jul 31, 2019 Trial start Phase 2: Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis source ↗
Feb 9, 2018 Trial start Phase 1: Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma source ↗
2016-01 Trial start Phase 1: A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects source ↗
2014-10 Trial start I: A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 source ↗
2014-07 Trial start Phase 1: 21 Day Cumulative Skin Irritation of RUT058-60 source ↗
2013-07 Trial start Phase 1: A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients source ↗
2012-08 Trial start Phase 1: Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers source ↗
2012-02 Trial start Phase 1: A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis source ↗
2011-02 Trial start Phase 1: Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118 source ↗
2010-04 Trial start —: Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum source ↗
2009-12 Trial start Phase 1: Effect of PUR003 on Asthma source ↗
2009-07 Trial start Phase 1: Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects source ↗

Clinical trials (lead sponsor) 15

Record	Title	Phase	Status	Start	Primary completion
NCT05667662	Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA	Phase 2	Terminated	Feb 1, 2023	Feb 27, 2024 (actual)
NCT05351086	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults	Phase 1	Completed	Jun 9, 2022	Sep 22, 2022 (actual)
NCT04759807	A Phase 1b Study of PUR1800 in Patients With COPD	1	Completed	Jan 4, 2021	Dec 2, 2021 (actual)
NCT03960606	Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis	Phase 2	Terminated	Jul 31, 2019	Jul 14, 2020 (actual)
NCT02280395	A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60	I	Terminated	2014-10	2015-06 (actual)
NCT03479411	Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma	Phase 1	Completed	Feb 9, 2018	Jun 28, 2018 (actual)
NCT00947687	Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects	Phase 1	Completed	2009-07	2009-09 (actual)
NCT02671825	A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects	Phase 1	Completed	2016-01	2016-03 (actual)
NCT02198963	21 Day Cumulative Skin Irritation of RUT058-60	Phase 1	Completed	2014-07	2014-08 (actual)
NCT01921712	A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients	Phase 1	Completed	2013-07	2013-12 (actual)
NCT01543191	A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis	Phase 1	Completed	2012-02	2012-12 (actual)
NCT01690949	Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers	Phase 1	Completed	2012-08	2013-04 (actual)
NCT01333904	Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118	Phase 1	Completed	2011-02	2012-06 (actual)
NCT00989521	Effect of PUR003 on Asthma	Phase 1	Completed	2009-12	2011-10 (actual)
NCT01096173	Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum	Not listed	Completed	2010-04	2010-06 (actual)

NIH awards 5

Annual award amounts. Total $2.2M.

Aug 14, 2013 NIH award 5U01AI082115-05 FY2013: $102,851 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CLARKE, ROBERT W; recipient as written: PULMATRIX, LEXINGTON, MA. Inhaled aerosols for prevention and treatment of source ↗
Aug 8, 2012 NIH award 5U01AI082115-04 FY2012: $283,013 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CLARKE, ROBERT W; recipient as written: PULMATRIX, LEXINGTON, MA. Inhaled aerosols for prevention and treatment of source ↗
Aug 19, 2011 NIH award 5U01AI082115-03 FY2011: $365,861 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CLARKE, ROBERT W; recipient as written: PULMATRIX, LEXINGTON, MA. Inhaled aerosols for prevention and treatment of source ↗
Aug 26, 2010 NIH award 5U01AI082115-02 FY2010: $699,622 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CLARKE, ROBERT W; recipient as written: PULMATRIX, LEXINGTON, MA. Inhaled aerosols for prevention and treatment of source ↗
Sep 16, 2009 NIH award 1U01AI082115-01 FY2009: $728,058 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CLARKE, ROBERT W; recipient as written: PULMATRIX, LEXINGTON, MA. Inhaled aerosols for prevention and treatment of source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-04-15 Raise Private raise (SEC Form D): $1.0M sold; issuer “Pulmatrix, Inc.”. Verified from the SEC filing. SEC filing ↗